We are live on ! Find out more
KRYS icon

Krystal Biotech
KRYS

90 hedge funds and large institutions have $635M invested in Krystal Biotech in 2019 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 31 increasing their positions, 31 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 6

62% more capital invested

Capital invested by funds: $393M → $635M (+$243M)

6% more funds holding

Funds holding: 85 → 90 (+5)

1.17% more ownership

Funds ownership: 65% → 66.17% (+1.2%)

0% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 31

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
90
Holders Change
+5
Holders Change %
+5.88%
% of All Funds
1.77%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
12
Increased
31
Reduced
31
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$19.3M
2
CS
Credit Suisse
Switzerland
+$10.4M
3
Goldman Sachs
Goldman Sachs
New York
+$3.92M
4
Citigroup
Citigroup
New York
+$2.3M
5
California Public Employees Retirement System
California Public Employees Retirement System
California
+$2.13M

Top Sellers

Rank Fund Capital Flow
1
VOYA Investment Management
VOYA Investment Management
Georgia
-$5.79M
2
KCM
Knoll Capital Management
Florida
-$4.17M
3
AG
Artal Group
Luxembourg
-$3.43M
4
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$2.7M
5
Verition Fund Management
Verition Fund Management
Connecticut
-$2.21M
Name Holding Trade Value Shares
Change 		Change in
Stake
EI
26
EAM Investors
California
$3.63M -$1.1M -22,451 -26%
William Blair & Company
27
William Blair & Company
Illinois
$3.53M +$258K +5,263 +9%
Citigroup
28
Citigroup
New York
$3.37M +$2.3M +46,937 +339%
SST
29
S Squared Technology
New York
$3.33M -$359K -7,318 -11%
ACM
30
Atika Capital Management
New York
$3.23M – – –
California Public Employees Retirement System
31
California Public Employees Retirement System
California
$3.15M +$2.13M +43,409 +322%
Wells Fargo
32
Wells Fargo
California
$2.44M +$1.35M +27,422 +166%
Neuberger Berman Group
33
Neuberger Berman Group
New York
$2.25M – – –
N
34
Nuveen
North Carolina
$2.19M -$56.2K -1,145 -3%
AA
35
ALPS Advisors
Colorado
$1.93M +$17.1K +348 +1%
Allianz Asset Management
36
Allianz Asset Management
Germany
$1.73M +$283K +5,759 +23%
ACH
37
ArrowMark Colorado Holdings
Colorado
$1.69M – – –
EGI
38
EAM Global Investors
California
$1.67M -$552K -11,259 -27%
MOACM
39
Mutual of America Capital Management
New York
$1.63M +$1.45M +29,460 New
TD Asset Management
40
TD Asset Management
Ontario, Canada
$1.44M +$29.4K +600 +2%
Verition Fund Management
41
Verition Fund Management
Connecticut
$1.34M -$2.21M -45,002 -65%
CIP
42
Chartwell Investment Partners
Pennsylvania
$1.27M -$1.1M -22,422 -50%
PPA
43
Parametric Portfolio Associates
Washington
$1.2M -$198K -4,041 -16%
Swiss National Bank
44
Swiss National Bank
Switzerland
$1.19M +$49.1K +1,000 +5%
JP Morgan Chase
45
JP Morgan Chase
New York
$1.09M +$800K +16,312 +474%
California State Teachers Retirement System (CalSTRS)
46
California State Teachers Retirement System (CalSTRS)
California
$906K – – –
New York State Common Retirement Fund
47
New York State Common Retirement Fund
New York
$859K +$24.5K +500 +3%
Morgan Stanley
48
Morgan Stanley
New York
$841K +$300K +6,105 +67%
State of Wisconsin Investment Board
49
State of Wisconsin Investment Board
Wisconsin
$725K – – –
Rafferty Asset Management
50
Rafferty Asset Management
New York
$693K -$692K -14,110 -53%
1
2
3 4

KRYS Hedge Fund Activity: Q4 2019 in Review

90 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q4 2019, worth a combined $635M — up 62% from $393M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new KRYS positions and 6 closed out — a net gain of 6 holders — while 31 added to existing stakes and 31 trimmed.

The largest buyer was OrbiMed, adding an estimated $19.3M. The largest seller was VOYA Investment Management, cutting an estimated $5.79M.

  • 90 institutional investors held Krystal Biotech (KRYS) as of Q4 2019, up from 85 in Q3 2019.
  • Funds reported $635M of Krystal Biotech stock for Q4 2019, up 62% quarter-over-quarter.
  • 12 funds opened new Krystal Biotech positions in Q4 2019 and 6 closed out, a net change of +6 holders.
  • The largest Krystal Biotech buyer in Q4 2019 was OrbiMed, an estimated $19.3M added.
  • The largest Krystal Biotech seller in Q4 2019 was VOYA Investment Management, an estimated $5.79M sold.

Based on aggregated 13F filings for Q4 2019.